Completed SNS-101 monotherapy and combination dose escalation through 15mg/kg with no dose limiting toxicities Company to present topline clinical data from the SNS-101 Phase 1 dose escalation study at the 2024 ASCO Annual Meeting Enrollment in the dose expansion portion of the clinical study advancing Strong balance sheet with cash runway into fourth quarter of 2025 BOSTON, May 09, 2024 (GLOBE NEWSWIRE) -- Sensei... Read More